Fasting-Mimicking Diet for Health & Longevity - Quick Reference Sheet

Fasting-Mimicking Diet for Health & Longevity

Created on 07/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A short, repeatable low-calorie eating pattern that briefly lowers calories, sugar, and protein to trigger a fasting-like state. The most consistent evidence shows modest drops in body weight, belly fat, and blood sugar, largest in those starting above ideal ranges. Broader longevity, brain, and immune claims rest mainly on animal and early studies. (Full Review)

Protocol

Cycle Length
5 days
~1,100 kcal on day 1; 700–800 kcal on days 2–5
Composition
Plant-based
Higher in healthy fats, low in protein and sugar
Frequency
Monthly to quarterly
Monthly for active goals; every 3–6 months for maintenance
Time to effect
Weight & Blood Sugar
Within 1 cycle
Initial shifts during the first 5-day cycle
Durable Benefits
Several months
Accumulate over repeated monthly cycles
Biological-Age Markers
~3 cycles
Shift estimated after three monthly cycles

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Underweight (BMI under 18.5) or frail
  • Adults over about 70 with low muscle mass
  • History of eating disorders
  • Type 1 diabetes
  • Advanced liver, kidney, or heart disease
  • Insulin use without supervision
Key Interactions
  • Glucose-lowering medications (insulin; sulfonylureas such as glipizide and glyburide)
  • Blood-pressure medications (ACE inhibitors such as lisinopril; diuretics such as hydrochlorothiazide)
  • Over-the-counter medications (NSAIDs such as ibuprofen; aspirin)
  • Medications that require food (metformin, some antibiotics)
  • Supplement interactions (iron; high-dose fat-soluble vitamins A, D, E, K)
  • Additive blood-sugar and blood-pressure supplements (berberine, cinnamon, magnesium, potassium)
  • Other metabolic interventions (prolonged water-only fasting, ketogenic diets, SGLT2 inhibitors such as empagliflozin)

Risk & Side Effects

  • High: Hunger, fatigue & weakness; headache & lightheadedness
  • Medium: Hypoglycemia in those on glucose-lowering medication; orthostatic hypotension & dizziness
  • Low: Lean mass loss with repeated cycling; gastrointestinal discomfort; sleep disturbance & irritability
  • Speculative: Triggering or worsening of disordered eating; gallstone formation from weight cycling; sarcopenia risk in frail older adults

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Tracks the diet's core metabolic effect
HbA1c <5.4% Reflects longer-term blood-sugar control
Fasting insulin 2–6 µIU/mL Sensitive early marker of insulin resistance
IGF-1 Mid-to-lower end of age-adjusted range The hormone the diet most directly lowers
hs-CRP <1.0 mg/L Marker of systemic inflammation
Triglycerides <80 mg/dL Fat metabolism and cardiometabolic risk
LDL cholesterol Context-dependent, generally <100 mg/dL Cholesterol tied to heart-disease risk
Blood pressure <120/80 mmHg Safety and cardiovascular benefit tracking
Electrolytes (sodium, potassium) Mid-normal range Safety during low food intake
eGFR >90 mL/min/1.73 m² Kidney function and safety

Cadence: Baseline in the week before the first cycle, after the first cycle, again at about 3 months (~three cycles), then every 6–12 months with continued cycling

Qualitative Assessment

  • Energy levels during and between cycles
  • Mental clarity and focus
  • Hunger and satiety patterns after refeeding
  • Sleep quality
  • Mood and stress resilience
  • Physical performance and recovery between cycles